IRADIMED CORPORATION. (NASDAQ:IRMD) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET
Company Participants
Roger Susi - President and Chief Executive Officer
Jack Glenn - CFO
Conference Call Participants
Frank Takkinen - Lake Street Capital Markets
Jason Wittes - ROTH Capital Partners
Operator
Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, October 31st, 2024, and contains time-sensitive accurate information only today. Earlier, IRadimed released its financial results for the second [sic] third quarter of 2024. A copy of this press release announcing the company's earnings is available under the heading News on our website at iradimed.com.
A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live over the Internet and on the company's website at iradimed.com, and a replay will be available on the website for the next 90 days.
Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are focused on future performance, results, plans and events that may include the company's expected future results. IRadimed reminds you that the future results may differ materially from those forward-looking statements due to several risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section of the company's most recent reports filed with the Securities and Exchange Commission, which may be obtained free from the SEC's website at sec.gov.
I would like to turn the call over to Roger Susi, President and Chief Executive Officer of IRadimed Corporation. Mr. Susi?
Roger Susi
Thank you, operator. Good morning, and thank you, everyone, for joining us on today's call. Once again, I'm very happy to report yet another record quarter, in fact our 13th consecutive record quarter. Driving this quarter was revenue coming in at $18.3 million. Recall that the previous quarter was $17.9 million, so growth continues to be attainable by all involved here at IRadimed.
In addition, gross profit remains impressive at 77.4%, with earnings very strong as well at $0.40 a diluted share. Again, pump orders remained strong and revenue likewise is following that strength, continued in this quarter as it had been in the previous two.